Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection

Trial Profile

Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs Clostridium difficile vaccine (Primary)
  • Indications Clostridium infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 30 Oct 2016 Results of three year follow up (extension phase) presented at the IDWeek 2016
    • 30 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov.
    • 26 Dec 2013 Protocol has been amended to add two treatment arms (explore different vaccination schedules using one of formulations)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top